• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Introduction to BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL- (CAS No. 851297-52-4)

BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL-, identified by the chemical compound code CAS No. 851297-52-4, is a specialized sulfonamide derivative that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, characterized by its unique structural motif of a benzene ring sulfonated at the 4-position and substituted with a bromo group at the 2-position, coupled with an N-(2-propenyl) amide moiety, exhibits a distinct set of chemical and biological properties that make it a promising candidate for further exploration in drug discovery and development.

The structural configuration of BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL- (CAS No. 851297-52-4) imparts upon it a high degree of reactivity and potential for diverse biological interactions. The presence of both the sulfonamide group and the bromo substituent enhances its solubility in polar solvents, facilitating its use in various biochemical assays and pharmaceutical formulations. Additionally, the N-(2-propenyl) amide side chain introduces a region of flexibility and potential for hydrogen bonding, which can be exploited to modulate its binding affinity to biological targets.

In recent years, sulfonamide derivatives have been extensively studied due to their broad spectrum of biological activities. These compounds are known to interact with enzymes and receptors in complex ways, often leading to inhibitory effects on various disease-related pathways. Specifically, BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL- (CAS No. 851297-52-4) has been investigated for its potential role in modulating inflammatory responses, bacterial resistance mechanisms, and even in the development of novel anticancer agents.

One of the most compelling aspects of BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL- (CAS No. 851297-52-4) is its ability to serve as a scaffold for structure-based drug design. The benzene sulfonamide core provides a rigid framework that can be modified to optimize interactions with specific biological targets, while the bromo group at the 2-position offers a handle for further functionalization through cross-coupling reactions or other synthetic methodologies. This versatility makes it an attractive building block for medicinal chemists seeking to develop new therapeutic agents.

Recent studies have highlighted the pharmacological potential of sulfonamide derivatives in treating various neurological disorders. For instance, modifications of the benzene sulfonamide moiety have been shown to enhance penetration through the blood-brain barrier, making compounds like BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL- (CAS No. 851297-52-4) particularly relevant for neurodegenerative diseases such as Alzheimer's and Parkinson's. The N-(2-propenyl) amide group has also been implicated in modulating neurotransmitter release and receptor activity, further supporting its therapeutic applications.

The synthesis of BENZENESULFONAMIDE, 2-BROMO-N-2-PROPENYL-* (CAS No. 85129752- 4) involves multi-step organic transformations that require careful optimization to ensure high yield and purity. Key steps include the bromination of benzenesulfonyl chloride followed by amidation with allylamine or another suitable nucleophile bearing the propenyl group. Advanced techniques such as palladium-catalyzed cross-coupling reactions may also be employed to introduce additional functional groups or to modify existing ones.

The physicochemical properties of this compound are also worth noting. Its molecular weight and solubility profile make it suitable for formulation in both aqueous and organic media, depending on the intended application. Furthermore, its stability under various storage conditions ensures that it can be reliably used in laboratory settings and potentially in industrial-scale production processes.

In conclusion, BENZENESULFONAMIDE, CAS No. 85129752- 4, represents a fascinating example of how structural complexity can lead to novel pharmacological activities. Its unique combination of functional groups makes it a valuable tool for researchers exploring new therapeutic strategies across multiple disease areas. As our understanding of molecular interactions continues to evolve, BENZENESULFONAMIDE, CAS No. 85129752- 4, will undoubtedly play an important role in shaping the future of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)